Auto Added by WPeMatico

UMediC Group Bhd’s 4QFY25 core profit after tax and minority interests came in at RM2.9m (+60.0% quarter-on-quarter, -6.2% year-on-year (YoY)), brought FY25 sum to RM8.2m (-15.4% YoY). This came in above our and consensus full year estimates.
The positive deviation stemmed primarily from the stronger-than-expected profit before tax (PBT) margin realised in the distribution division.
As such, we raised our FY26-27 profit forecasts by +16%/+12% to mainly reflect higher PBT margin assumptions for its distribution division. Despite the earnings revision (which led to higher target price), we maintain our Hold rating on UMedic as share price has run ahead of fundamentals. — HLIB Research, a unit of Hong Leong Investment Bank Bhd (Sep 12, 2025)
(Calls by analysts tracked by Bloomberg: 1 Buy, 2 Hold, 0 Sell; Consensus target price: 39 sen)
The post UMediC retains Hold, target price up at 36 sen appeared first on The Malaysian Reserve.